NR 601 Final Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NR 601 Primary Care of the Maturing and Aged Family Practicum Final Exam 2026-2027 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource contains 250 actual questions and verified answers for
the NR 601 Final Exam at Chamberlain University. Designed for the 2026/2027 academic year, it
covers all key topics in primary care of the maturing and aged family, including geriatric syndromes,
chronic disease management, and preventive care. Each question includes rationales and distractor
explanations to reinforce learning. This document is your guaranteed path to a passing grade.
Key Features:
Geriatric assessment and screening tools
Management of common chronic conditions in older adults
Pharmacotherapy considerations in aging
Health promotion and disease prevention
Ethical and legal issues in geriatric care
Transitional care and end-of-life planning
Updates for 2026:
- Updated to reflect 2026/2027 Chamberlain NR 601 curriculum
- Incorporated latest clinical guidelines from AGS and USPSTF
- Added new questions on COVID-19 management in older adults
- Revised rationales for clarity and accuracy
- Enhanced distractor explanations to address common misconceptions
Abstract:
This exam preparation document is meticulously compiled from actual NR 601 Final Exam questions at
Chamberlain University, ensuring alignment with the 2026/2027 course objectives. It provides 250 verified
questions with detailed answers and rationales, covering comprehensive geriatric assessment, management of
multimorbidity, pharmacotherapy, and preventive care. The content is organized by core content areas, each with
specified question ranges and weightings to facilitate targeted study. Updated to incorporate the latest
evidence-based guidelines, this resource is designed to optimize exam performance and clinical reasoning in
primary care for the maturing and aged population. Each question includes distractor explanations to deepen
understanding and reduce errors. This document is an essential tool for achieving a high score and mastering the
competencies required for advanced practice nursing in gerontology.
Keywords:
NR 601 final exam, primary care older adults, geriatric nursing, Chamberlain University, exam prep 2026, 250
questions, graded A+, geriatric syndromes
Answer Format:
Each question is followed by the correct answer in bold, with a detailed rationale explaining the underlying clinical
reasoning. Distractor options are analyzed to clarify why they are incorrect, addressing common pitfalls and
misconceptions. This format reinforces evidence-based practice and critical thinking.
Compliance Checklist:
All questions verified from actual NR 601 final exams
Answers graded A+ by course faculty
Updated to 2026/2027 academic year guidelines
Page 1
, Includes rationales and distractor explanations
Organized by content area with weightings
Guaranteed to help pass the exam
Content Area Overview:
Content Area Questions Key Topics Weight
Geriatric Assessment and 1-50 Comprehensive geriatric assessment, 20%
Screening functional status, cognitive screening, fall
risk, polypharmacy
Chronic Disease Management 51-120 Hypertension, diabetes, heart failure, COPD, 28%
osteoarthritis, dementia
Pharmacotherapy in Aging 121-160 Age-related pharmacokinetics, Beers 16%
criteria, medication reconciliation, adverse
drug reactions
Preventive Care and Health 161-200 Immunizations, cancer screening, 16%
Promotion osteoporosis prevention, nutrition, exercise
Ethical, Legal, and End-of-Life 201-230 Advance directives, capacity assessment, 12%
Issues palliative care, elder abuse, surrogate
decision-making
Transitional Care and Health 231-250 Care transitions, home health, skilled 8%
Systems nursing, Medicare/Medicaid,
interprofessional collaboration
Page 2
,Q1. A patient with advanced chronic kidney disease (eGFR 20 mL/min/1.73m²) requires initiation
of a statin for primary prevention of cardiovascular events. Which statin is most appropriate given
the degree of renal impairment?
A. Atorvastatin 40 mg daily
B. Rosuvastatin 10 mg daily
C. Simvastatin 20 mg daily
D. Pravastatin 40 mg daily
Correct Answer: A. Atorvastatin 40 mg daily
Rationale: Atorvastatin is primarily hepatically metabolized and does not require dose adjustment in
chronic kidney disease (CKD), even with eGFR <30. Rosuvastatin has limited renal excretion but
requires dose reduction (max 10 mg) in severe CKD, making it less ideal for initiation at 10 mg.
Simvastatin is contraindicated in severe CKD due to increased risk of myopathy. Pravastatin requires
dose reduction in severe CKD. Therefore, atorvastatin is the safest and most effective choice for primary
prevention in this patient.
Why Wrong:
B - Rosuvastatin 10 mg is the maximum recommended dose in severe CKD, but atorvastatin is
preferred for primary prevention due to more robust evidence and no need for dose adjustment.
C - Simvastatin is contraindicated in severe CKD (eGFR <30) due to increased risk of myopathy and
rhabdomyolysis.
D - Pravastatin requires dose reduction in severe CKD and has less evidence for primary prevention
in this population compared to atorvastatin.
Reference: Whelton, P.K., et al. (2018). 2017 ACC/AHA Guideline for the Prevention, Detection,
Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol, 71(19),
e127-e248.
Q2. Which of the following is the most appropriate initial pharmacotherapy for a patient with newly
diagnosed hypertension and stage 3 chronic kidney disease (eGFR 45 mL/min/1.73m², no
proteinuria)?
A. Amlodipine 5 mg daily
B. Hydrochlorothiazide 12.5 mg daily
C. Lisinopril 10 mg daily
D. Metoprolol succinate 50 mg daily
Correct Answer: C. Lisinopril 10 mg daily
Rationale: For patients with CKD and hypertension, ACE inhibitors (or ARBs) are recommended as
first-line therapy due to their renoprotective effects, even in the absence of proteinuria, as they slow
progression of CKD. Amlodipine is a second-line agent unless there is a compelling indication. Thiazide
diuretics become less effective in stage 3 CKD (eGFR <45) and are not preferred. Beta-blockers are not
first-line for hypertension without a concurrent indication like heart failure or coronary artery disease.
Why Wrong:
B - Hydrochlorothiazide is less effective at eGFR <45 and is not first-line for CKD-related
hypertension.
D - Beta-blockers are not first-line for hypertension in CKD unless there is a compelling indication
such as heart failure.
Reference: Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. (2021).
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic
Kidney Disease. Kidney Int, 99(3S), S1-S87.
Page 3
, Q3. A patient with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD)
is already on metformin and empagliflozin. HbA1c is 8.5%. Which of the following is the most
appropriate next agent to add?
A. Glipizide
B. Sitagliptin
C. Liraglutide
D. Insulin glargine
Correct Answer: C. Liraglutide
Rationale: In patients with type 2 diabetes and established ASCVD, guidelines recommend a GLP-1
receptor agonist (e.g., liraglutide) with proven cardiovascular benefit as the preferred third agent after
metformin and an SGLT2 inhibitor. Glipizide increases risk of hypoglycemia and weight gain, with no
cardiovascular benefit. Sitagliptin has neutral cardiovascular effects. Insulin glargine is effective but not
preferred over GLP-1 agonists for cardiovascular risk reduction.
Why Wrong:
B - Sitagliptin is a DPP-4 inhibitor with neutral cardiovascular effects and is not preferred over
GLP-1 agonists for ASCVD.
D - Insulin is effective for glycemic control but does not provide the cardiovascular benefits seen
with GLP-1 agonists in this population.
Reference: American Diabetes Association. (2026). Standards of Care in Diabetes-2026. Diabetes Care,
49(Suppl 1), S1-S264.
Q4. A patient with heart failure with reduced ejection fraction (HFrEF, LVEF 35%) is on optimal
doses of metoprolol succinate, lisinopril, and spironolactone. Despite this, he remains symptomatic
(NYHA class II-III). Which medication class has been shown to reduce mortality in this scenario?
A. Ivabradine
B. Sacubitril/valsartan
C. Digoxin
D. Hydralazine/isosorbide dinitrate
Correct Answer: B. Sacubitril/valsartan
Rationale: Sacubitril/valsartan (ARNI) is recommended to replace ACE inhibitors in patients with
HFrEF who remain symptomatic on optimal medical therapy, as it has shown superior reduction in
mortality and hospitalizations. Ivabradine is indicated only if heart rate is 70 bpm despite beta-blocker
therapy, and it reduces hospitalizations but not mortality. Digoxin reduces hospitalizations but not
mortality. Hydralazine/isosorbide dinitrate is reserved for African American patients who remain
symptomatic on standard therapy, but ARNI is preferred in the general population.
Why Wrong:
C - Digoxin reduces heart failure hospitalizations but has no mortality benefit.
D - Hydralazine/isosorbide dinitrate is indicated specifically for African American patients with
HFrEF, not as first-line add-on for all patients.
Reference: Heidenreich, P.A., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of
Heart Failure. Circulation, 145(18), e895-e1032.
Page 4
Verified Questions
NR 601 Primary Care of the Maturing and Aged Family Practicum Final Exam 2026-2027 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource contains 250 actual questions and verified answers for
the NR 601 Final Exam at Chamberlain University. Designed for the 2026/2027 academic year, it
covers all key topics in primary care of the maturing and aged family, including geriatric syndromes,
chronic disease management, and preventive care. Each question includes rationales and distractor
explanations to reinforce learning. This document is your guaranteed path to a passing grade.
Key Features:
Geriatric assessment and screening tools
Management of common chronic conditions in older adults
Pharmacotherapy considerations in aging
Health promotion and disease prevention
Ethical and legal issues in geriatric care
Transitional care and end-of-life planning
Updates for 2026:
- Updated to reflect 2026/2027 Chamberlain NR 601 curriculum
- Incorporated latest clinical guidelines from AGS and USPSTF
- Added new questions on COVID-19 management in older adults
- Revised rationales for clarity and accuracy
- Enhanced distractor explanations to address common misconceptions
Abstract:
This exam preparation document is meticulously compiled from actual NR 601 Final Exam questions at
Chamberlain University, ensuring alignment with the 2026/2027 course objectives. It provides 250 verified
questions with detailed answers and rationales, covering comprehensive geriatric assessment, management of
multimorbidity, pharmacotherapy, and preventive care. The content is organized by core content areas, each with
specified question ranges and weightings to facilitate targeted study. Updated to incorporate the latest
evidence-based guidelines, this resource is designed to optimize exam performance and clinical reasoning in
primary care for the maturing and aged population. Each question includes distractor explanations to deepen
understanding and reduce errors. This document is an essential tool for achieving a high score and mastering the
competencies required for advanced practice nursing in gerontology.
Keywords:
NR 601 final exam, primary care older adults, geriatric nursing, Chamberlain University, exam prep 2026, 250
questions, graded A+, geriatric syndromes
Answer Format:
Each question is followed by the correct answer in bold, with a detailed rationale explaining the underlying clinical
reasoning. Distractor options are analyzed to clarify why they are incorrect, addressing common pitfalls and
misconceptions. This format reinforces evidence-based practice and critical thinking.
Compliance Checklist:
All questions verified from actual NR 601 final exams
Answers graded A+ by course faculty
Updated to 2026/2027 academic year guidelines
Page 1
, Includes rationales and distractor explanations
Organized by content area with weightings
Guaranteed to help pass the exam
Content Area Overview:
Content Area Questions Key Topics Weight
Geriatric Assessment and 1-50 Comprehensive geriatric assessment, 20%
Screening functional status, cognitive screening, fall
risk, polypharmacy
Chronic Disease Management 51-120 Hypertension, diabetes, heart failure, COPD, 28%
osteoarthritis, dementia
Pharmacotherapy in Aging 121-160 Age-related pharmacokinetics, Beers 16%
criteria, medication reconciliation, adverse
drug reactions
Preventive Care and Health 161-200 Immunizations, cancer screening, 16%
Promotion osteoporosis prevention, nutrition, exercise
Ethical, Legal, and End-of-Life 201-230 Advance directives, capacity assessment, 12%
Issues palliative care, elder abuse, surrogate
decision-making
Transitional Care and Health 231-250 Care transitions, home health, skilled 8%
Systems nursing, Medicare/Medicaid,
interprofessional collaboration
Page 2
,Q1. A patient with advanced chronic kidney disease (eGFR 20 mL/min/1.73m²) requires initiation
of a statin for primary prevention of cardiovascular events. Which statin is most appropriate given
the degree of renal impairment?
A. Atorvastatin 40 mg daily
B. Rosuvastatin 10 mg daily
C. Simvastatin 20 mg daily
D. Pravastatin 40 mg daily
Correct Answer: A. Atorvastatin 40 mg daily
Rationale: Atorvastatin is primarily hepatically metabolized and does not require dose adjustment in
chronic kidney disease (CKD), even with eGFR <30. Rosuvastatin has limited renal excretion but
requires dose reduction (max 10 mg) in severe CKD, making it less ideal for initiation at 10 mg.
Simvastatin is contraindicated in severe CKD due to increased risk of myopathy. Pravastatin requires
dose reduction in severe CKD. Therefore, atorvastatin is the safest and most effective choice for primary
prevention in this patient.
Why Wrong:
B - Rosuvastatin 10 mg is the maximum recommended dose in severe CKD, but atorvastatin is
preferred for primary prevention due to more robust evidence and no need for dose adjustment.
C - Simvastatin is contraindicated in severe CKD (eGFR <30) due to increased risk of myopathy and
rhabdomyolysis.
D - Pravastatin requires dose reduction in severe CKD and has less evidence for primary prevention
in this population compared to atorvastatin.
Reference: Whelton, P.K., et al. (2018). 2017 ACC/AHA Guideline for the Prevention, Detection,
Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol, 71(19),
e127-e248.
Q2. Which of the following is the most appropriate initial pharmacotherapy for a patient with newly
diagnosed hypertension and stage 3 chronic kidney disease (eGFR 45 mL/min/1.73m², no
proteinuria)?
A. Amlodipine 5 mg daily
B. Hydrochlorothiazide 12.5 mg daily
C. Lisinopril 10 mg daily
D. Metoprolol succinate 50 mg daily
Correct Answer: C. Lisinopril 10 mg daily
Rationale: For patients with CKD and hypertension, ACE inhibitors (or ARBs) are recommended as
first-line therapy due to their renoprotective effects, even in the absence of proteinuria, as they slow
progression of CKD. Amlodipine is a second-line agent unless there is a compelling indication. Thiazide
diuretics become less effective in stage 3 CKD (eGFR <45) and are not preferred. Beta-blockers are not
first-line for hypertension without a concurrent indication like heart failure or coronary artery disease.
Why Wrong:
B - Hydrochlorothiazide is less effective at eGFR <45 and is not first-line for CKD-related
hypertension.
D - Beta-blockers are not first-line for hypertension in CKD unless there is a compelling indication
such as heart failure.
Reference: Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. (2021).
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic
Kidney Disease. Kidney Int, 99(3S), S1-S87.
Page 3
, Q3. A patient with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD)
is already on metformin and empagliflozin. HbA1c is 8.5%. Which of the following is the most
appropriate next agent to add?
A. Glipizide
B. Sitagliptin
C. Liraglutide
D. Insulin glargine
Correct Answer: C. Liraglutide
Rationale: In patients with type 2 diabetes and established ASCVD, guidelines recommend a GLP-1
receptor agonist (e.g., liraglutide) with proven cardiovascular benefit as the preferred third agent after
metformin and an SGLT2 inhibitor. Glipizide increases risk of hypoglycemia and weight gain, with no
cardiovascular benefit. Sitagliptin has neutral cardiovascular effects. Insulin glargine is effective but not
preferred over GLP-1 agonists for cardiovascular risk reduction.
Why Wrong:
B - Sitagliptin is a DPP-4 inhibitor with neutral cardiovascular effects and is not preferred over
GLP-1 agonists for ASCVD.
D - Insulin is effective for glycemic control but does not provide the cardiovascular benefits seen
with GLP-1 agonists in this population.
Reference: American Diabetes Association. (2026). Standards of Care in Diabetes-2026. Diabetes Care,
49(Suppl 1), S1-S264.
Q4. A patient with heart failure with reduced ejection fraction (HFrEF, LVEF 35%) is on optimal
doses of metoprolol succinate, lisinopril, and spironolactone. Despite this, he remains symptomatic
(NYHA class II-III). Which medication class has been shown to reduce mortality in this scenario?
A. Ivabradine
B. Sacubitril/valsartan
C. Digoxin
D. Hydralazine/isosorbide dinitrate
Correct Answer: B. Sacubitril/valsartan
Rationale: Sacubitril/valsartan (ARNI) is recommended to replace ACE inhibitors in patients with
HFrEF who remain symptomatic on optimal medical therapy, as it has shown superior reduction in
mortality and hospitalizations. Ivabradine is indicated only if heart rate is 70 bpm despite beta-blocker
therapy, and it reduces hospitalizations but not mortality. Digoxin reduces hospitalizations but not
mortality. Hydralazine/isosorbide dinitrate is reserved for African American patients who remain
symptomatic on standard therapy, but ARNI is preferred in the general population.
Why Wrong:
C - Digoxin reduces heart failure hospitalizations but has no mortality benefit.
D - Hydralazine/isosorbide dinitrate is indicated specifically for African American patients with
HFrEF, not as first-line add-on for all patients.
Reference: Heidenreich, P.A., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of
Heart Failure. Circulation, 145(18), e895-e1032.
Page 4
